AVEO Oncology (AVEO) Misses Q1 EPS by 26c

AVEO Oncology (NASDAQ: AVEO) reported Q1 EPS of ($0.81), $0.26 worse than the analyst estimate of ($0.55). Revenue for the quarter came in at $1.92 million versus the consensus estimate of $1.01 million.

• U.S. Commercial Launch Underway with Fully Deployed Sales Force Following FDA Approval of FOTIVDA® (tivozanib) on March 10, 2021 –
• FOTIVDA Net Product Revenue of $1.1 Million from Initial Distributor Orders in the Last Week of Q1; All Distributors Have Placed Reorders for Q2 –
• Entered Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb for Planned Pivotal Phase 3 TiNivo-2 Study of FOTIVDA in Combination with OPDIVO® (nivolumab); Study Anticipated to Commence Mid-2021 –
• Phase 2 Open Label Randomized Study Results of Ficlatuzumab in HNSCC to be Presented at ASCO; Phase 3 Decision Anticipated Mid-2021 –

For earnings history and earnings-related data on AVEO Oncology (AVEO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15